Aphria, Tilray merge to make cannabis colossus
Entity with equity value of about $4.8B, $874M sales born from all-stock deal
Tilray Inc. and Aphria Inc. agreed to combine their operations, forming a new giant in the fast-growing cannabis industry.
The all-stock deal, which puts together two of the market's best known names, will create an entity with an equity value of about $4.8 billion, according to a statement and interviews late Tuesday with Tilray and Aphria leaders. The combined group's 12-month sales of $874 million surpasses that of industry leaders such as Curaleaf Holdings Inc. and Canopy Growth Corp.
The new company will keep Tilray's name and trade under its ticker on the Nasdaq, and Aphria shareholders will own 62 per cent of Tilray's stock under the terms of the transaction, which was characterized as a “reverse acquisition of Tilray.” Leamington, Ont.-based Aphria will pay a 23-per-cent premium to Tilray's Dec. 15 closing price of US$7.87.
“I realized that Aphria needed to expand out of Canada, and merging with Tilray was a great answer because it's a U.s.-domiciled business with great international assets,” said Aphria chief executive Irwin Simon, who will be chairman and CEO of the combined group.
Aphria gained as much as 6.5 per cent Wednesday in New York, while Tilray rose as much as 26 per cent.
The deal reinforces that cannabis, still seen by some as a fringe investment, is a fast-evolving sector as more U.S. states legalize the substance and an increasing number of European countries open up to its medical use. The industry has seen a flurry of deals as companies jockey for position amid rapidly changing rules. Tilray and Aphria's combined assets represent an early step toward that goal of creating a global cannabis operation.
Tilray CEO Brendan Kennedy will become a board member of the combined company. Kennedy and Simon first met in 2018, but the financial courtship only began this year.
The new company will sell cannabis products across Canada and “be well-positioned to pursue growth opportunities” such as medical marijuana in Germany. The companies said Tilray's Portugal production facility will allow tariff-free access to the European Union.
Simon and Kennedy said the deal better positions them to take advantage of potential U.S federal legalization and is also built on the prospect of more legalization in Europe. Kennedy said Aphria's two assets in Germany — a distribution centre for medical prescriptions and a cultivation facility — were particularly attractive.
“We felt with this deal, we could not only win in Canada, but win in Europe,” he said.
A combination of beverage assets will also result. Aphria had earlier agreed to acquire U.S. craft beer company Sweetwater Brewing Company, which makes cannabis-infused beverages, and Tilray is a partner of Anheuser-busch Inbev. The combined U.S. operations will focus on Sweetwater and Manitoba Harvest, which makes branded hemp and CBD products.
Simon said there's an interest in using Tilray's beverage facility in Canada to get Aphria into making drinks that contain THC, which is the active ingredient in cannabis.
“The combined company is expected to have a strong, flexible balance sheet, cash balance and access to capital giving it the ability to accelerate growth and deliver attractive returns for stockholders,” according to a joint statement.
The firms say the tie-up, which needs shareholder approval from Tilray, will reduce annual costs by about $100 million before taxes within 24 months of completion. The agreement, which is expected to close in the second quarter of 2021, includes a right to match higher bids and a reciprocal termination fee of $65 million under certain circumstances.
BNN Bloomberg Television earlier reported that Aphria and Tilray were in advanced talks. Through Tuesday's close, Tilray shares have fallen 54 per cent in 2020, while Aphria's have risen 56 per cent.
Bloomberg Intelligence analysts Ken Shea and Gopal Srinivasan said in a research note that the combination “would offer several benefits,” including “expanded reach into international medical cannabis markets.”
The European market will grow to US$359 million in 2020, up 25 per cent from 2019, according to Brightfield Group, a cannabis consulting firm.
The U.S. remains the biggest prize, however. With its widespread recreational use, it's expected to represent 70 per cent of the world's Us$93.8-billion market by 2025, according to Euromonitor International.